MERUS N V's ticker is MRUS and the CUSIP is N5749R100. A total of 94 filers reported holding MERUS N V in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.9%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,221,999 | +30.4% | 179,050 | +45.6% | 0.00% | – |
| Q2 2023 | $3,238,774 | +44.6% | 123,007 | +1.1% | 0.00% | – |
| Q1 2023 | $2,239,758 | +18.9% | 121,726 | 0.0% | 0.00% | – |
| Q4 2022 | $1,883,101 | -25.6% | 121,726 | -3.6% | 0.00% | – |
| Q3 2022 | $2,530,000 | +0.9% | 126,266 | +14.0% | 0.00% | – |
| Q2 2022 | $2,507,000 | -21.6% | 110,716 | -8.4% | 0.00% | – |
| Q1 2022 | $3,196,000 | -16.4% | 120,889 | +0.5% | 0.00% | – |
| Q4 2021 | $3,824,000 | +37.5% | 120,251 | -4.9% | 0.00% | – |
| Q3 2021 | $2,782,000 | +19.0% | 126,436 | +14.0% | 0.00% | – |
| Q2 2021 | $2,338,000 | +38.6% | 110,932 | +37.4% | 0.00% | – |
| Q1 2021 | $1,687,000 | +74.1% | 80,732 | +46.1% | 0.00% | – |
| Q4 2020 | $969,000 | +50.5% | 55,254 | +2.8% | 0.00% | – |
| Q3 2020 | $644,000 | -28.7% | 53,741 | -4.3% | 0.00% | – |
| Q2 2020 | $903,000 | – | 56,150 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Medicxi Ventures Management (Jersey) Ltd | 1,600,000 | $32,048,000 | 13.34% |
| Lynx1 Capital Management LP | 613,071 | $12,280,000 | 11.08% |
| Aquilo Capital Management, LLC | 1,507,109 | $30,187,000 | 10.88% |
| COMMODORE CAPITAL LP | 2,615,762 | $52,394,000 | 8.42% |
| MPM BioImpact LLC | 918,310 | $18,394,000 | 4.36% |
| BVF INC/IL | 3,444,420 | $68,992,000 | 2.85% |
| Boxer Capital, LLC | 1,900,000 | $38,057,000 | 2.14% |
| Opaleye Management Inc. | 253,200 | $5,072,000 | 2.10% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 295,136 | $5,912,000 | 2.00% |
| TCG Crossover Management, LLC | 300,000 | $6,009,000 | 1.80% |